Advocacy groups form a buyer’s club to obtain generic versions of pricey Vertex cystic fibrosis drug
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
Dan seems to be pushing himself as a creator with his new Absurd Ventures. Dan was asked in the recent IGN interview how he set about writing Rockstar’s games. Senior executive editor Ryan McAffrey ...
One of the highlights of my first three years as a literature professor at MIT—and indeed, of my 15-year career as an educator—has been the recent discovery that some of my students, past and present, ...
From traditional scripts to modern styles, this art form offers a creative outlet and a chance to connect with history – here are tips from Hong Kong artists Samantha Cheung, Kalo Chu and Kaye Shu ...
Hosted on MSN
Is Vertex Pharmaceuticals Stock a Buy?
Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about 16% ...
Over the past decade, Vertex Pharmaceuticals (NASDAQ: VRTX) has delivered above-average returns. The secret behind the biotech's success isn't much of a secret. The drugmaker developed and marketed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback